期刊
FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.890522
关键词
systemic lupus erythematosus; prevention; biomarkers; risk factors; pathogenesis
类别
资金
- Lupus Foundation of America Gary S. Gilkeson Career Development Award
- NIH [K24 AR066109, R01 AR057327]
- McCaig Institute for Bone and Joint Health
There is evidence that patients with systemic lupus erythematosus (SLE) have markers of inflammation and autoimmunity before the diagnosis. Understanding the preclinical phase of SLE can help identify at-risk patients and implement preventative strategies.
There is growing evidence that preceding the diagnosis or classification of systemic lupus erythematosus (SLE), patients undergo a preclinical phase of disease where markers of inflammation and autoimmunity are already present. Not surprisingly then, even though SLE management has improved over the years, many patients will already have irreversible disease-related organ damage by time they have been diagnosed with SLE. By gaining a greater understanding of the pathogenesis of preclinical SLE, we can potentially identify patients earlier in the disease course who are at-risk of transitioning to full-blown SLE and implement preventative strategies. In this review, we discuss the current state of knowledge of SLE preclinical pathogenesis and propose a screening and preventative strategy that involves the use of promising biomarkers of early disease, modification of lifestyle and environmental risk factors, and initiation of preventative therapies, as examined in other autoimmune diseases such as rheumatoid arthritis and type 1 diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据